| Name | Title | Contact Details |
|---|
The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.
Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
Orphan Star Therapeutics, LLC, a biopharmaceutical company, develops therapies for rare genetic diseases including Canavan disease, glut1 deficiency, and rare genetic skin diseases.
Lyophilization Services of New England is a Bedford, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fette America is a Rockaway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.